Review
Neurosciences
Amir Valizadeh, Mohammad Reza Fattahi, Maryam Sadeghi, Mehrnush Saghab Torbati, Mohammad Ali Sahraian, Amir Reza Azimi
Summary: The study found that DMTs can reduce the number and volume of T1 hypointense lesions in MS patients, but these findings need to be interpreted cautiously due to high heterogeneity values. The results suggest that DMTs have a certain impact on the progression of the disease in MS patients.
CNS NEUROSCIENCE & THERAPEUTICS
(2022)
Article
Biochemistry & Molecular Biology
Oliver Neuhaus, Wolfgang Koehler, Florian Then Bergh, Wolfgang Kristoferitsch, Juergen Faiss, Thorsten Rosenkranz, Dirk Reske, Robert Patejdl, Hans-Peter Hartung, Uwe K. Zettl
Summary: This study aimed to investigate the correlation between clinical, neuropsychological, and immunological parameters in RRMS patients with fatigue before and during treatment with GA. After 12 months of treatment, 13 patients showed improvement in all three fatigue assessment scales, while 5 patients deteriorated and 7 patients showed inconsistent effects. Fatigue and overall quality of life improved, but no clear correlation between clinical and molecular effects of GA was found in RRMS patients with fatigue.
Review
Clinical Neurology
Francesca Washington, Dawn Langdon
Summary: Research shows that patients with multiple sclerosis often struggle with treatment adherence, influenced by factors such as age, gender, emotions, cognition, and treatment satisfaction. Targeted patient support programs should be developed to improve treatment compliance.
JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Tomas Kalincik, Ibrahima Diouf, Sifat Sharmin, Charles Malpas, Tim Spelman, Dana Horakova, Eva Kubala Havrdova, Maria Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Duquette, Pierre Grammond, Vilija Jokubaitis, Anneke Van der Walt, Francois Grand'Maison, Patrizia Sola, Diana Ferraro, Vahid Shaygannejad, Raed Alroughani, Raymond Hupperts, Murat Terzi, Cavit Boz, Jeannette Lechner-Scott, Eugenio Pucci, Vincent Van Pesch, Franco Granella, Roberto Bergamaschi, Daniele Spitaleri, Mark Slee, Steve Vucic, Radek Ampapa, Pamela McCombe, Cristina Ramo-Tello, Julie Prevost, Javier Olascoaga, Edgardo Cristiano, Michael Barnett, Maria Laura Saladino, Jose Luis Sanchez-Menoyo, Suzanne Hodgkinson, Csilla Rozsa, Stella Hughes, Fraser Moore, Cameron Shaw, Ernest Butler, Olga Skibina, Orla Gray, Allan Kermode, Tunde Csepany, Bhim Singhal, Neil Shuey, Imre Piroska, Bruce Taylor, Magdolna Simo, Carmen-Adella Sirbu, Attila Sas, Helmut Butzkueven
Summary: The study demonstrates that continued treatment with MS immunotherapies significantly reduces disability accrual, risk of needing a walking aid, and frequency of relapses over a 15-year period.
Article
Clinical Neurology
Martin Valis, Zbysek Pavelek, Michal Novotny, Blanka Klimova, Jana Sarlakova, Simona Haluskova, Marek Peterka, Ivana Stetkarova, Pavel Stourac, Jan Mares, Pavel Hradilek, Radek Ampapa, Marta Vachova, Eva Recmanova, Eva Meluzinova
Summary: This study analyzed the characteristics and treatment of pediatric patients with multiple sclerosis. The results showed that these patients usually start disease-modifying drug treatment at the age of 15.89, with moderate and mild relapses being common. Moreover, the first-choice treatment is similar to that of adult patients, but low efficacy or lack of tolerance may lead to treatment discontinuation in children.
FRONTIERS IN NEUROLOGY
(2022)
Article
Biochemistry & Molecular Biology
Ignacio Casanova, Maria I. Dominguez-Mozo, Laura De Torres, Yolanda Aladro-Benito, Angel Garcia-Martinez, Patricia Gomez, Sara Abellan, Esther De Antonio, Roberto Alvarez-Lafuente
Summary: This study investigates the association between a preselected list of miRNAs in the serum of relapsing-remitting multiple sclerosis (RRMS) patients with therapeutic response to Glatiramer Acetate (GA) and clinical evolution. The findings suggest that certain miRNAs may serve as potential biomarkers for disease progression and response to treatment in multiple sclerosis.
Review
Clinical Neurology
Massimiliano Mirabella, Pietro Annovazzi, Wallace Brownlee, Jeffrey A. Cohen, Christoph Kleinschnitz, Christian Wolf
Summary: Earlier diagnosis, access to disease-modifying therapies, and improved supportive care have positively influenced the disease course of multiple sclerosis, leading to improved long-term outcomes for patients. However, the complexity of treatment selection has increased due to the presence of comorbidities, immune senescence, and the growing number of approved therapies.
FRONTIERS IN NEUROLOGY
(2022)
Article
Clinical Neurology
Mathilde Lefort, Sandra Vukusic, Romain Casey, Gilles Edan, Emmanuelle Leray
Summary: Early treatment initiation has a significant impact on disability progression in patients with relapsing-remitting multiple sclerosis (RRMS), reducing the risk of disability development, particularly in older patients.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Article
Medicine, Research & Experimental
Paulina Maria Reyes-Mata, Argelia Esperanza Rojas-Mayorquin, Lucrecia Carrera-Quintanar, Celia Gonzalez-Castillo, Mario Alberto Mireles-Ramirez, Jose de Jesus Guerrero-Garcia, Daniel Ortuno-Sahagun
Summary: This study aimed to investigate the serum levels of Pleiotrophin (PTN) in patients with Multiple Sclerosis (MS). The results showed that PTN serum levels were significantly higher in RRMS patients compared to the healthy control group, and were associated with sex, body mass index (BMI), and IFN-beta treatment.
ARCHIVES OF MEDICAL RESEARCH
(2022)
Review
Clinical Neurology
Dejan Jakimovski, Samreen Awan, Svetlana P. Eckert, Osman Farooq, Bianca Weinstock-Guttman
Summary: POMS is a rare neuroinflammatory and neurodegenerative disease that affects a small percentage of patients before the age of 18. Differential diagnosis is necessary before treatment initiation to exclude other similar acquired demyelinating syndromes. Currently, only two MS DMTs have been approved for pediatric use.
Review
Clinical Neurology
Marco Biolato, Assunta Bianco, Matteo Lucchini, Antonio Gasbarrini, Massimiliano Mirabella, Antonio Grieco
Summary: This review analyzed data on hepatotoxicity of disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis, finding that while serious liver adverse events are rare, the exact incidence is unknown, and all current DMTs for multiple sclerosis have potential hepatic toxic effects.
Article
Clinical Neurology
Gisela Zanga, Estefania Drzewiscki, Paula Tagliani, Maximiliano Smietniansky, Maria M. Esnaola y Rojas, Diego Caruso
Summary: This study conducted a telephone survey to identify predictors related to adherence to disease modifying therapies (DMTs) in MS patients in Argentina, and found that oral medication and higher educational level were associated with better adherence.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2021)
Article
Chemistry, Multidisciplinary
Dina Erzina, Alice Capecchi, Sacha Javor, Jean-Louis Reymond
Summary: Researchers synthesized a library of peptide dendrimers with an amino acid composition similar to GA, some of which were as active as GA. Detailed profiling showed that the best hit dendrimer can induce the differentiation of monocytes towards an M2 state with a distinct immune marker profile. This peptide dendrimer might serve as a starting point to develop a well-defined immunomodulatory analog of GA.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
(2021)
Review
Clinical Neurology
F. Schweitzer, S. Laurent, G. R. Fink, Michael H. Barnett, H. P. Hartung, C. Warnke
Summary: This review summarizes the predicted and unintended adverse effects of disease-modifying therapies for multiple sclerosis on leukocytes in peripheral blood, highlighting the importance of vigilance for potential therapeutic risks when prescribing medications.
JOURNAL OF NEUROLOGY
(2021)
Article
Clinical Neurology
Mahmoud A. AbdelRazek, Subhash Tummala, Fariha Khalid, Shahamat Tauhid, Youmna Jalkh, Samar Khalil, Shelley Hurwitz, Jonathan Zurawski, Rohit Bakshi
Summary: This study compared gray matter atrophy in patients with multiple sclerosis (MS) treated with glatiramer acetate (GA) and patients with clinically benign MS (BMS). The results showed that there was no significant change in gray matter and whole brain atrophy in the GA group over 2 years, similar to the BMS group.
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2023)
Article
Clinical Neurology
S. Llufriu, E. Aguera, L. Costa-Frossard, V. Galan, L. Landete, D. Lourido, J. E. Meca-Lallana, E. Moral, F. Bravo-Rodriguez, L. Koren, A. Labiano, A. Leon, P. Martin, M. D. Monedero, L. Requeni, I. Zubizarreta, A. Rovira
Summary: Coordination between neurologists and neuroradiologists is crucial for the diagnosis and follow-up of MS patients. However, communication between these departments can be improved in many Spanish hospitals. The research team developed a series of good practice guidelines to optimize coordination between these departments and improve the diagnosis and follow-up of MS patients.
Article
Clinical Neurology
Marta Bellofatto, Alessandro Bertini, Irene Tramacere, Fiore Manganelli, Gian Maria Fabrizi, Angelo Schenone, Lucio Santoro, Tiziana Cavallaro, Marina Grandis, Stefano C. Previtali, Isabella Allegri, Luca Padua, Costanza Pazzaglia, Daniela Calabrese, Paola Saveri, Aldo Quattrone, Paola Valentino, Stefano Tozza, Luca Gentile, Massimo Russo, Anna Mazzeo, Giuseppe Vita, Sylvie Piacentini, Chiara Pisciotta, Davide Pareyson
Summary: A significant proportion of Charcot-Marie-Tooth disease (CMT) patients experience general distress and depression, which are correlated with disease severity and medication usage.
JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Ibrahima Diouf, Charles B. Malpas, Sifat Sharmin, Izanne Roos, Dana Horakova, Eva Kubala Havrdova, Francesco Patti, Vahid Shaygannejad, Serkan Ozakbas, Guillermo Izquierdo, Sara Eichau, Marco Onofrj, Alessandra Lugaresi, Raed Alroughani, Alexandre Prat, Marc Girard, Pierre Duquette, Murat Terzi, Cavit Boz, Francois Grand'Maison, Sherif Hamdy, Patrizia Sola, Diana Ferraro, Pierre Grammond, Recai Turkoglu, Katherine Buzzard, Olga Skibina, Bassem Yamout, Ayse Altintas, Oliver Gerlach, Vincent van Pesch, Yolanda Blanco, Davide Maimone, Jeannette Lechner-Scott, Roberto Bergamaschi, Rana Karabudak, Gerardo Iuliano, Chris McGuigan, Elisabetta Cartechini, Michael Barnett, Stella Hughes, Maria Jose Sa, Claudio Solaro, Ludwig Kappos, Cristina Ramo-Tello, Edgardo Cristiano, Suzanne Hodgkinson, Daniele Spitaleri, Aysun Soysal, Thor Petersen, Mark Slee, Ernest Butler, Franco Granella, Koen de Gans, Pamela McCombe, Radek Ampapa, Bart Van Wijmeersch, Anneke van der Walt, Helmut Butzkueven, Julie Prevost, L. G. F. Sinnige, Jose Luis Sanchez-Menoyo, Steve Vucic, Guy Laureys, Liesbeth Van Hijfte, Dheeraj Khurana, Richard Macdonell, Riadh Gouider, Tamara Castillo-Trivino, Orla Gray, Eduardo Aguera-Morales, Abdullah Al-Asmi, Cameron Shaw, Norma Deri, Talal Al-Harbi, Yara Fragoso, Tunde Csepany, Angel Perez Sempere, Irene Trevino-Frenk, Jan Schepel, Fraser Moore, Tomas Kalincik
Summary: This study evaluated the impact of patient characteristics on the response to disease-modifying therapy (DMT) in multiple sclerosis (MS). The results showed that patients with relapsing MS who received DMT had a reduced relapse incidence, lower risk of disability worsening, and greater chance of disability improvement. The effectiveness of DMT was influenced by the severity of disability, prior relapse rate, and prior cerebral magnetic resonance imaging activity, but not by age.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Review
Clinical Neurology
Stijn Swinnen, Dries De Wit, Liesbeth Van Cleemput, Catherine Cassiman, Benedicte Dubois
Summary: This study conducted a qualitative systematic review to evaluate the predictive value of retinal layer measurement by spectral-domain optical coherence tomography (SD-OCT) in multiple sclerosis (MS) patients, and found that measuring retinal layer thickness can predict disability progression in MS patients, particularly in those with a relapsing-remitting disease pattern (RRMS).
JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Simona Toscano, Clara Grazia Chisari, Adriana Meli, Chiara Finocchiaro, Salvatore Lo Fermo, Mario Zappia, Francesco Patti
Summary: The study found that there have been changes in pregnancy planning and management for women with multiple sclerosis (MS) over the past 15 years. Nowadays, more women of childbearing age are being treated with high-efficacy disease-modifying drugs (DMD) during pregnancy, leading to a reduced relapse rate before and after delivery without increased obstetric complications.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)
Article
Clinical Neurology
Francesco Patti, Clara Grazia Chisari, Simona Toscano, Pietro Annovazzi, Paola Banfi, Roberto Bergamaschi, Raffaella Clerici, Marta Zaffira Conti, Antonio Cortese, Roberta Fantozzi, Diana Ferraro, Mariano Fischetti, Maura Frigo, Maurizia Gatto, Paolo Immovilli, Stefania Leoni, Simona Malucchi, Giorgia Maniscalco, Girolama Alessandra Marfia, Damiano Paolicelli, Paola Perini, Carlo Serrati, Rocco Totaro, Gabriella Turano, Paola Valentino, Mauro Zaffaroni, Cristina Zuliani, Diego Centonze
Summary: This study aimed to evaluate the association between cognitive profile, attitude, and preferences of patients concerning treatment choice in multiple sclerosis. The results showed that more than 50% of patients chose a collaborative role in making treatment decisions, and these patients had higher cognitive abilities.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)
Article
Clinical Neurology
Cyrus Daruwalla, Vahid Shaygannejad, Serkan Ozakbas, Eva Kubala Havrdova, Dana Horakova, Raed Alroughani, Cavit Boz, Francesco Patti, Marco Onofrj, Alessandra Lugaresi, Sara Eichau, Marc Girard, Alexandre Prat, Pierre Duquette, Bassem Yamout, Samia J. Khoury, Seyed Aidin Sajedi, Recai Turkoglu, Ayse Altintas, Olga Skibina, Katherine Buzzard, Pierre Grammond, Rana Karabudak, Anneke van der Walt, Helmut Butzkueven, Davide Maimone, Jeannette Lechner-Scott, Aysun Soysal, Nevin John, Julie Prevost, Daniele Spitaleri, Cristina Ramo-Tello, Oliver Gerlach, Gerardo Iuliano, Matteo Foschi, Radek Ampapa, Vincent van Pesch, Michael Barnett, Nevin Shalaby, Marie D'hooghe, Jens Kuhle, Maria Jose Sa, Marzena Fabis-Pedrini, Allan Kermode, Saloua Mrabet, Riadh Gouider, Suzanne Hodgkinson, Guy Laureys, Liesbeth Van Hijfte, Richard Macdonell, Celia Oreja-Guevara, Edgardo Cristiano, Pamela McCombe, Jose Luis Sanchez-Menoyo, Bhim Singhal, Yolanda Blanco, Stella Hughes, Justin Garber, Claudio Solaro, Chris McGuigan, Bruce Taylor, Koen de Gans, Mario Habek, Abdullah Al-Asmi, Simu Mihaela, Tamara Castillo Trivino, Talal Al-Harbi, Juan Ignacio Rojas, Orla Gray, Dheeraj Khurana, Bart Van Wijmeersch, Nikolaos Grigoriadis, Jihad Inshasi, Jiwon Oh, Eduardo Aguera-Morales, Yara Fragoso, Fraser Moore, Cameron Shaw, Seyed Mohammad Baghbanian, Neil Shuey, Barbara Willekens, Todd A. Hardy, Danny Decoo, Angel Perez Sempere, Deborah Field, Ray Wynford-Thomas, Nick G. Cunniffe, Izanne Roos, Charles B. Malpas, Alasdair J. Coles, Tomas Kalincik, J. William L. Brown, MSBase Study Grp
Summary: This study found that early non-disabling relapses in people with RRMS are associated with a higher risk of disability accumulation, which may be mitigated by high-efficacy DMTs. Therefore, treatment decisions should take into account the impact of non-disabling relapses.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Clinical Neurology
Izanne Roos, Ibrahima Diouf, Sifat Sharmin, Dana Horakova, Eva Kubala Havrdova, Francesco Patti, Vahid Shaygannejad, Serkan Ozakbas, Guillermo Izquierdo, Sara Eichau, Marco Onofrj, Alessandra Lugaresi, Raed Alroughani, Alexandre Prat, Marc Girard, Pierre Duquette, Murat Terzi, Cavit Boz, Francois Grand'Maison, Patrizia Sola, Diana Ferraro, Pierre Grammond, Recai Turkoglu, Katherine Buzzard, Olga Skibina, Bassem Yamou, Ayse Altintas, Oliver Gerlach, Vincent van Pesch, Yolanda Blanco, Davide Maimone, Jeannette Lechner-Scott, Roberto Bergamaschi, Rana Karabudak, Chris McGuigan, Elisabetta Cartechini, Michael Barnett, Stella Hughes, Maria Jose Sa, Claudio Solaro, Cristina Ramo-Tello, Suzanne Hodgkinson, Daniele Spitaleri, Aysun Soysal, Thor Petersen, Franco Granella, Koen de Gans, Pamela McCombe, Radek Ampapa, Bart Van Wijmeersch, Anneke van der Walt, Helmut Butzkueven, Julie Prevost, Jose Luis Sanchez-Menoyo, Guy Laureys, Riadh Gouider, Tamara Castillo-Trivino, Orla Gray, Eduardo Aguera-Morales, Abdullah Al-Asmi, Cameron Shaw, Norma Deri, Talal Al-Harbi, Yara Fragoso, Tunde Csepany, Angel Perez Sempere, Irene Trevino-Frenk, Jan Schepel, Fraser Moore, Charles Malpas, Tomas Kalincik
Summary: In this study, propensity score matching and marginal structural models were used to compare the relative effectiveness of fingolimod and natalizumab. The results showed that natalizumab treatment was associated with a lower risk of relapse and a higher probability of disability improvement. There was no significant difference in the magnitude of effect between the two methods.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Medicine, General & Internal
Javier Villena-Salinas, Simeon Jose Ortega-Lozano, Tomader Amrani-Raissouni, Eduardo Aguera, Javier Caballero-Villarraso
Summary: The study aimed to evaluate the effectiveness of [I-123]Ioflupane SPECT in diagnosing MSA at the initial clinical suspicion. The results showed that SPECT had high sensitivity and positive predictive value, making it a useful tool for diagnosing MSA and distinguishing between subtypes.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Clinical Neurology
Susana Sainz de la Maza, Rocio Gomez-Ballesteros, Monica Borges, Jesus Martin-Martinez, Javier Sotoca, Ana Alonso, Ana B. Caminero, Laura Borrega, Jose L. Sanchez-Menoyo, Francisco J. Barrero-Hernandez, Carmen Calles, Luis Brieva, Maria R. Blasco-Quilez, Julio Dotor Garcia-Soto, Maria del Campo-Amigo, Laura Navarro-Canto, Eduardo Aguera, Moises Garces-Redondo, Olga Carmona, Laura Gabaldon-Torres, Lucia Forero, Mariona Hervas, Nicolas Medrano, Jorge Maurino, Tamara Castillo-Trivino
Summary: This multicenter, non-interventional study examined whether patient-reported outcome measures (PROMs) could capture disability in early-stage relapsing-remitting multiple sclerosis (RRMS) patients. The study found that disability progression occurs independently of relapse activity, even in the early stages of RRMS. PROMs can assist clinicians in disease monitoring and decision-making by allowing early-stage RRMS patients to communicate their perceived disability in different domains.
MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL
(2023)
Article
Clinical Neurology
Sifat Sharmin, Izanne Roos, Steve Simpson-Yap, Charles Malpes, Marina M. Sanchez, Serkan Ozakbas, Dana Horakova, Eva K. Havrdova, Francesco Patti, Raed Alroughani, Guillermo Izquierdo, Sara Eichau, Cavit Boz, Magd Zakaria, Marco Onofrj, Alessandra Lugaresi, Bianca Weinstock-Guttman, Alexandre Prat, Marc Girard, Pierre Duquette, Murat Terzi, Maria Pia Amato, Rana Karabudak, Francois Grand'Maison, Samia J. Khoury, Pierre Grammond, Jeannette Lechner-Scott, Katherine Buzzard, Olga Skibina, Anneke van der Walt, Helmut Butzkueven, Recai Turkoglu, Ayse Altintas, Davide Maimone, Allan Kermode, Nevin Shalaby, Vincent V. Pesch, Ernest Butler, Youssef Sidhom, Riadh Gouider, Saloua Mrabet, Oliver Gerlach, Aysun Soysal, Michael Barnett, Jens Kuhle, Stella Hughes, Maria J. Sa, Suzanne Hodgkinson, Celia Oreja-Guevara, Radek Ampapa, Thor Petersen, Cristina Ramo-Tello, Daniele Spitaleri, Pamela McCombe, Bruce Taylor, Julie Prevost, Matteo Foschi, Mark Slee, Chris McGuigan, Guy Laureys, Liesbeth V. Hijfte, Koen de Gans, Claudio Solaro, Jiwon Oh, Richard Macdonell, Eduardo Aguera-Morales, Bhim Singhal, Orla Gray, Justin Garber, Bart V. Wijmeersch, Mihaela Simu, Tamara Castillo-Trivino, Jose L. Sanchez-Menoyo, Dheeraj Khurana, Abdullah Al-Asmi, Talal Al-Harbi, Norma Deri, Yara Fragoso, Patrice H. Lalive, L. G. F. Sinnige, Cameron Shaw, Neil Shuey, Tunde Csepany, Angel P. Sempere, Fraser Moore, Danny Decoo, Barbara Willekens, Claudio Gobbi, Jennifer Massey, Todd Hardy, John Parratt, Tomas Kalincik
Summary: There are geographical variations in the incidence and prevalence of multiple sclerosis globally. Latitude, as well as other lifestyle and environmental factors, is considered to be a major driver of this variation. This study examined the risk of secondary progressive multiple sclerosis in relation to latitude and country of residence, with consideration of high-to-moderate efficacy immunotherapy, in a geographically diverse cohort. The findings suggest that higher latitude is associated with a higher probability of developing secondary progressive multiple sclerosis, but high-to-moderate efficacy immunotherapy can reduce this risk.
Article
Neurosciences
Begona M. Escribano, Ana Munoz-Jurado, Evelio Luque, Alberto Galvan, Manuel Latorre, Javier Caballero-Villarraso, Ana I. Giraldo, Eduardo Aguera, Isaac Tunez
Summary: Stress is implicated in the pathological features of Multiple Sclerosis (MS). Various therapies have shown promise in reducing oxidative stress in an animal model of MS. This study aims to test the antioxidant effect of transcranial magnetic stimulation (TMS), extra virgin olive oil (EVOO), and S-allyl cysteine (SAC) and compare their efficacy. Combination therapies do not appear to be more effective than individual therapies.
Article
Clinical Neurology
Bruno Brochet, Alessandra Solari, Jeannette Lechner-Scott, Fredrik Piehl, Dawn Langdon, Raymond Hupperts, Krzysztof Selmaj, Francesco Patti, Luis Brieva, Eva Maria Maida, Nektaria Alexandri, Andrzej Smyk, Axel Nolting, Birgit Keller, Xavier Montalban, Eva Kubala Havrdova
Summary: Cladribine tablet treatment significantly improved the health-related quality of life in people with highly active relapsing multiple sclerosis, with good safety and tolerability.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Meeting Abstract
Clinical Neurology
Susana Sainz de la Maza, Rocio Gomez-Ballesteros, Monica Borges, Jesus Martin-Martinez, Javier Sotoca, Ana Alonso, Ana B. Caminero, Laura Borrega, Jose L. Sanchez-Menoyo, Francisco J. Barrero-Hernandez, Carmen Calles, Luis Brieva, Maria R. Blasco-Quilez, Julio Dotor Garcia-Soto, Maria del Campo-Amigo, Laura Navarro-Canto, Eduardo Aguera, Moises Garces-Redondo, Olga Carmona, Laura Gabaldon-Torres, Lucia Forero, Mariona Hervas, Jorge Maurino, Tamara Castillo-Trivino
Meeting Abstract
Clinical Neurology
Tamara Castillo-Trivino, Rocio Gomez-Ballesteros, Monica Borges, Jesus Martin-Martinez, Javier Sotoca, Ana Alonso, Ana B. Caminero, Laura Borrega, Jose L. Sanchez-Menoyo, Francisco J. Barrero-Hernandez, Carmen Calles, Luis Brieva, Maria R. Blasco-Quilez, Julio Dotor Garcia-Soto, Maria del Campo-Amigo, Laura Navarro-Canto, Eduardo Aguera, Moises Garces-Redondo, Olga Carmona, Laura Gabaldon-Torres, Lucia Forero, Mariona Hervas, Paloma Lopez-Laiz, Jorge Maurino, Susana Sainz de la Maza